Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at [email protected].
The Food and Drug Administration in May approved 7 therapies to treat patients with non-small cell lung cancer. And although one expert notes that few are considered “practice changing”, patients should not be disheartened considering there have been so many advancements in the treatment of the disease.
Although the study failed to meet its goal of progression-free survival, overall survival data are currently not yet available, and follow-up will continue until the next planned analysis.
Most of the data from the recent approvals of several non-small cell lung cancer drugs don’t distinguish themselves regarding efficacy or safety to what was already available before the flurry of approvals in May, according to Dr. Timothy Burns.
Ten percent of women who received a hysterectomy and salpingectomy, or removal of the fallopian tubes, during the study period had a family history of breast or ovarian cancer.
A recent data analysis found that most women diagnosed with ovarian cancer (92%) experienced abdominal and pelvic-related symptoms and visited a physician with this complaint anywhere from six to 70 months prior to diagnosis.
“Having new options is important, particularly when patients have already been through chemotherapy and some of the other therapies that are available,” said Dr. John P. Leonard.
“One FDA approval that we were quite excited about (is Tabrecta). And I've actually already put some patients on it; it's a very good drug,” Dr. Timothy Burns said in a recent interview.
The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual and only a fraction of them are considered practice changing, according to Dr. Timothy Burns.
Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.
Data from a phase 3 study presented at the 2020 ASCO Virtual Scientific Program showed that treatment with savolitinib demonstrated encouraging efficacy and an improved safety over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary renal cell carcinoma.
The risk for a major cardiovascular event was reduced by more than half in patients who received Relumina compared to the hormone associated therapy leuprolide.
A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.
“We learned from previous prospective studies (that) using chemoimmunotherapy for those patients with TP53 aberrations, the survival data compared with others that do not harbor this mutation are much less favorable,” said Dr. Jia Ruan.
“It is important to note that the data predates the widespread use of BTK inhibitors and even cellular therapies such as CAR T-cell therapy, specifically,” Dr. Reem Karmali said in an interview. “And so, it doesn't reliably reflect the potential advancements and survival that we've been able to achieve with these novel targeted therapies.”
“As people go through the process, it’s important that you don't minimize community health workers that are not certified because at the end of the day that paper doesn't create the bond,” says Rosalia Guerrero-Luera.
“I think that when people are diagnosed with cancer, cancer really becomes their life,” Alessandra Tantawi said in a recent interview with CURE®. “And it's so hard to just have a ‘normal day’ where you can focus on anything besides cancer. And I think what's important is to spend time that is outside of the cancer treatment.”
“I had the honor of spending time with Kathy at CURE's inaugural Ovarian Cancer Heroes ceremony. She was such a nice, helpful person and did so much for the cancer survivor community,” one Facebook user wrote about CURE Magazine co-founder Kathy LaTour.
“With a new administration route, Phesgo offers an outpatient option for patients to receive (Perjeta) and (Herceptin),” Dr. Richard Pazdur said in a press release issued by the FDA.
In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.
In an interview with CURE®, Dr. Mazyar Shadman discussed the enormous variety of treatment preferences among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.
There are three things that should be considered when deciding what is the optimal treatment in the first line setting for patients with chronic lymphocytic leukemia (CLL), according to Dr. Mazyar Shadman.
The Food and Drug Administration approved Keytruda to treat patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be treated with surgery or radiation.
The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.
In this episode of the “CURE Talks Cancer” podcast, we spoke with a breast surgical oncologist and gynecologic surgeon about why the topic of gynecologic health is a taboo subject when it comes to cancer treatment, and what patients can do to treat those changes.
According to data presented at the 2020 ASCO Virtual Scientific Program, increasing the dose of thoracic radiotherapy from the standard measurement of dosing improved survival in patients with limited-disease small cell lung cancer.
According to lead study author Dr. Luis Paz-Ares, study findings confirm the use of the immunotherapy Imfinzi in combination with etoposide plus cisplatin or carboplatin (EP) as a new frontline standard of care for this patient population.
After a median follow-up of 13.3 months, the median overall response rate across all patients who received idecabtagene vicleucel (ide-cel) was 73%, including a complete response of 33%.
The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute myeloid leukemia (AML).
"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.
The Food and Drug Administration (FDA) has approved Zepzelca (lurbinectedin) for adults with metastatic small cell lung cancer (SCLC) whose disease progressed on or after receiving platinum-based chemotherapy.
